Fenofibrate-d6

Fenofibrate-d6 is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Product Specifications

CAS Number

[1092484-56-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Cytochrome P450; Isotope-Labeled Compounds; PPAR

Type

Isotope-Labeled Compounds

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cardiovascular Disease; Cancer

Purity

99.70

Solubility

10 mM in DMSO|DMSO : ≥ 15mg/mL

Smiles

ClC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(C(OC(C)C)=O)(C([2H])([2H])[2H])C([2H])([2H])[2H])=O

Molecular Formula

C20H15D6ClO4

Molecular Weight

366.87

Precautions

H302, H315, H319, H335

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Schelleman H, et al. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol. 2014 Sep;78 (3) :639-48.|[3]Gong Y, et al. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine. 2016 Sep 30. pii: S2352-3964 (16) 30448-0.